In addition, a subset of patients with SLE/LN fails to respond to current standard immuno-therapy. There is an urgent need to develop steroid-sparing treatment regimens as well as novel therapies for the management of refractory disease. Rituximab is a chimeric mouse/human monoclonal antibody ...
showed that crossreactive anti-dsDNA/ NMDAR autoantibodies selectively damaged mouse hippocampal neurons. These anti- dsDNA/NMDAR-treated mice also performed more poorly than control mice (treated with anti-dsDNA/NMDAR– sera) in behavioral and cognitive tests that required flexible memory; however, ...
showed that crossreactive anti-dsDNA/ NMDAR autoantibodies selectively damaged mouse hippocampal neurons. These anti- dsDNA/NMDAR-treated mice also performed more poorly than control mice (treated with anti-dsDNA/NMDAR– sera) in behavioral and cognitive tests that required flexible memory; however, ...
(EAE) mouse model, [64Cu]Cu-rituximab uptake was higher in the lumbar spinal cord of EAE mice expressing human CD20 on B cells than in the spinal cord of healthy mice (James et al., 2017). Thus, humanized anti-20 antibodies hold promise as tracers for the imaging of autoimmune ...
In a pilot study four patients with systemic lupus erythematosus (SLE) and autoimmune thrombocytopenia (ITP) were treated with rituximab, a Bcell depleting chimeric human/mouse anti-CD20 antibody. Treatment could be performed without serious side effects and resulted in a depletion of B cells from...
Clinical trials using rituximab in RA Rituximab is a mouse–human chimeric monoclonal antibody that has a murine variable region that is specific for CD20, an antigen found on the surface of B cells in their earlier stages of development prior to the plasma cell stage. The IgG1 heavy and ...
Rituximab is a chimeric human/mouse monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) refractory to anti-tumour necrosis factor (TNF) therapy.1 Rituximab seems to be efficient in other diseases such as autoimmune cytopoenia,2 systemic lupus erythaematosus (SLE)...
Rituximab is a chimeric human/mouse monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) refractory to anti-tumour necrosis factor (TNF) therapy.1 Rituximab seems to be efficient in other diseases such as autoimmune cytopoenia,2 systemic lupus erythaematosus (SLE)...
In a pilot study four patients with systemic lupus erythematosus (SLE) and autoimmune thrombocytopenia (ITP) were treated with rituximab, a Bcell depleting chimeric human/mouse anti-CD20 antibody. Treatment could be performed without serious side effects and resulted in a depletion of B cells from...
Rituximab, the first chimeric, mouse-human monoclonal antibody which is directed against CD20, seems to be a new therapeutic option. The purpose of this review is to explain the current clinical evidence on the therapeutic use of rituximab in adult SLE patients. Two randomized clinical trials ...